Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.43 |
| ▸ | KDM5A | P29375 | 6/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 2/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868479 | 0.81 | KDM4C (0.52) | KDM4CKDM5ACA12CA1CA9 | |
| SCHEMBL7082287 | 0.81 | KDM4C (0.43) | KDM4CKDM5ACA12CA1CA9 | |
| SCHEMBL8337243 | 0.79 | ALDH1A1 (0.54) | KDM4CKDM5ACA12CA1CA9 | |
| SCHEMBL8415760 | 0.79 | KDM4C (0.42) | KDM4CKDM5ACA12CA1CA9 | |
| SCHEMBL31198188 | 0.79 | KDM4C (0.50) | KDM4CKDM5ACA12CA1CA9 | |
| SCHEMBL10655777 | 0.75 | S1PR2 (0.42) | KDM4CKDM5ACA12CA1CA9 | |
| Acetic Acid SCHEMBL3416510 | 0.75 | KDM4C (0.55) | KDM4CKDM5ACA12CA1CA9 | |
| SCHEMBL7783595 | 0.75 | CA12 (0.50) | CA12CA9ALDH1A1 | |
| SCHEMBL168312 | 0.74 | KDM4C (0.53) | KDM4CKDM5AKDM4APHF8S1PR2 | |
| SCHEMBL14064830 | 0.74 | GGPS1 (0.47) | KDM4CKDM5AKDM4APHF8S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | KDM4C 2984/4885KDM5A 2389/4885CA12 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.